STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancer

STAT News·October 15, 2026 at 3:43 PM

statnews.com

Verastem Oncology reports encouraging early results for its KRAS G12D inhibitor, which it’s studying in more than 200 patients with advanced solid tumors like metastatic pancreatic ductal adenocarcinoma and non-small…

Read source

Chat about this story

Quick actions

More stories

STAT News1 day ago

STAT+: RevMed’s pancreatic cancer drug nears European approval

STAT News2 days ago

Merck and Moderna have ‘lot of exploring to do’ after initial cancer vaccine success

STAT News2 days ago

After a melanoma diagnosis, mRNA cancer vaccine delivered a patient hope — and a path forward

Pro

Currencies

Last updated 1 day ago

17°

Isolated showers

High 17°

Low 5°

Sat

17°

5°

Sun

15°

2°

Mon

17°

5°

Tue

19°

12°

Wed

17°

10°

Markets

Last updated 1 day ago

8,908.43+0.78%